Moderna and Merck Cancer Vaccine Hits Major Milestone in Phase 3 Trial
Moderna and Merck announced on Wednesday that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large Phase 3 clinical trial. This milestone marks the first time a personalized mRNA cancer vaccine has succeeded in such a trial, according to TradingKey.
The trial involved 1,137 high-risk melanoma patients who had undergone surgery and found that adding Moderna's vaccine significantly delayed cancer recurrence compared to using Merck's Keytruda alone. The trial met its primary objective, with the two companies yet to release full Phase 3 data at a future medical conference.
The vaccine uses mRNA technology to create a tailored treatment for individual patients, analyzing their tumor characteristics and creating a targeted vaccine that helps the body recognize and attack cancer cells more accurately.
This success is significant for Moderna as it looks to diversify its revenue streams beyond COVID-19 vaccines. The company's stock surged over 100% in pre-market trading following the announcement, with investors expecting a major new growth driver from this product pipeline.